Merck-Moderna Phase 3 Win Validates Tempus AI's Personalis Bet, Stock Jumps 18%
TEM sits 46% above its 52-week low of $40.77.
Summary
Merck and Moderna's INTerpath-001 Phase 3 trial met its primary endpoint, marking the first successful late-stage readout for a personalized mRNA cancer therapy. The trial used Personalis's genomic tumor-profiling platform to identify neoantigens, directly validating the technology Tempus AI agreed to acquire for $1.5 billion last month. Tempus shares jumped 17.77% to $58.13 as traders connected the clinical win to the pending acquisition. CEO Eric Lefkofsky publicly congratulated the partners and emphasized Tempus's role in supporting the program. This external validation materially strengthens the strategic rationale for the Personalis deal and could accelerate commercial adoption of its MRD and sequencing offerings.
At the time of this announcement, TEM was trading at $59.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.7B. The 52-week trading range was $40.77 to $104.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.